Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02652676 · ClinicalTrials.gov registry record · NA
Reversible Pulmonary Artery Banding as Simplified Management of End-stage Dilated Left Ventriculopathy in Early Life
A NA study, sponsored by Loma Linda University.
- Terminated
- Registry status
- NA
- Development phase
- 4
- Enrollment target
NCT02652676 is a NA study that was terminated before completion, run by Loma Linda University. The registered enrollment target is 4 participants.
The verdict
NCT02652676, a NA study, was terminated before completion, sponsored by Loma Linda University.
- TERMINATED
- Registry status
- NA
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to: 1) Remodel and restore left ventricular geometry and function. 2) Avoid the need for mechanical circulatory support (MCS) and/or cardiac transplantation (CT). 3) Confirm the outcomes of a pilot study completed in Germany and reported in The Journal of Heart and Lung Transplantation in May 2013.
Interventions
- PROCEDURE Reversible Pulmonary Artery Banding
- PROCEDURE GORE-TEX DualMesh EMERGE PLUS Biomaterial
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2016-01 |
| Est. Completion | 2021-05-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02652676
The ClinicalTrials.gov registry entry for NCT02652676 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Loma Linda University, which has 237 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Reversible Pulmonary Artery Banding is the first listed.
NCT02652676 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02652676 about?
NCT02652676 is a clinical study titled "Reversible Pulmonary Artery Banding as Simplified Management of End-stage Dilated Left Ventriculopathy in Early Life". The purpose of this study is to: 1) Remodel and restore left ventricular geometry and function. 2) Avoid the need for mechanical circulatory support (MCS) and/or cardiac transplantation (CT). 3) Confirm the outcomes of a pilot study completed in Germany and reported in The Journal of Heart and Lung ...
What is the current status of trial NCT02652676?
This trial is currently terminated. It is a NA study. The enrollment target is 4 participants. The study started on 2016-01. Estimated completion is 2021-05-07.
What interventions are being tested in trial NCT02652676?
The interventions under investigation include: Reversible Pulmonary Artery Banding (PROCEDURE), GORE-TEX DualMesh EMERGE PLUS Biomaterial (PROCEDURE).
Who is sponsoring clinical trial NCT02652676?
This trial is sponsored by Loma Linda University, which has 237 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.